Vaxart Inc (VXRT)
0.7289
-0.02
(-2.68%)
USD |
NASDAQ |
May 03, 16:00
0.7419
+0.01
(+1.78%)
After-Hours: 20:00
Vaxart Research and Development Expense (Annual): 68.14M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 68.14M |
| December 31, 2022 | 81.05M |
| December 31, 2021 | 48.75M |
| December 31, 2020 | 19.86M |
| December 31, 2019 | 14.54M |
| December 31, 2018 | 17.28M |
| June 30, 2017 | 28.30M |
| June 30, 2016 | 26.30M |
| June 30, 2015 | 19.80M |
| June 30, 2014 | 17.50M |
| June 30, 2013 | 15.50M |
| December 31, 2011 | 17.76M |
| December 31, 2010 | 26.08M |
| December 31, 2009 | 16.49M |
| Date | Value |
|---|---|
| December 31, 2008 | 12.56M |
| December 31, 2007 | 18.84M |
| December 31, 2006 | 28.74M |
| December 31, 2005 | 57.79M |
| December 31, 2004 | 59.55M |
| December 31, 2003 | 29.04M |
| December 31, 2002 | 21.10M |
| December 31, 2001 | 15.33M |
| December 31, 2000 | 14.27M |
| December 31, 1999 | 15.50M |
| December 31, 1998 | 21.80M |
| December 31, 1997 | 19.10M |
| December 31, 1996 | 16.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
14.54M
Minimum
2019
81.05M
Maximum
2022
46.47M
Average
48.75M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Novavax Inc | 737.50M |
| aTyr Pharma Inc | 42.29M |
| Allogene Therapeutics Inc | 242.91M |
| AIM ImmunoTech Inc | 10.94M |
| Protalix BioTherapeutics Inc | 17.09M |